Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardioangiologica 2016 June;64(3) > Minerva Cardioangiologica 2016 June;64(3):339-53

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as
Share

 

REVIEWS   

Minerva Cardioangiologica 2016 June;64(3):339-53

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Advances with polymer-free amphilimus-eluting stents

Didier CARRIÉ

Department of Cardiology, University Hospital Rangueil, Toulouse, France


PDF


Despite the improved clinical outcomes following the availability of second generation drug eluting stents (DES), percutaneous coronary intervention (PCI) is associated with worse clinical and angiographic outcomes among the patients with diabetes mellitus (DM) than among non-diabetics. The Cre8 Amphilimus-eluting DES is polymer-free, resulting in a reduced inflammatory response and lower risk of stent thrombosis. In a clinical study, it showed equivalent efficacy and safety in diabetic and non-diabetic populations, a unique finding among DES studies. These findings were confirmed in a real-world study, Investig8, and another real-world study, Particip8, is ongoing. The RESERVOIR Clinical Trial recruited patients with DM and showed noninferiority of the Cre8 DES compared to an everolimus eluting DES (EES) in the overall group but showed a statistical superiority of Cre8 in diabetic patients with higher metabolic dysfunctions. The Cre8 DES is therefore a valuable option for this important patient population.

top of page